Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial
Latest Information Update: 17 Aug 2022
Price :
$35 *
At a glance
- Drugs Azvudine (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors HRH Pharmaceuticals
- 10 Aug 2022 Status changed from recruiting to completed.
- 07 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.
- 07 Feb 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Mar 2022.